Conclusion
All‐trans retinoic acid combined with low‐dose apatinib might be a potential efficacy therapeutic option for patients with R/M ACCHN. This finding will be further confirmed by our registered ongoing trial, the APLUS study (NCT 04433169).All‐rans retinoic acid combined with low‐dose apatinib might be a potential efficacy therapeutic option for patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck 
